At this year’s LSX World Congress in Boston, an entire track was devoted to Obesity Science and Innovation, with pharma ...

Already a blockbuster therapy for advanced breast cancer and other indications like gastric cancer, Enhertu made revenues of ...

Investors were spooked by the miss, and shares in Nasdaq-listed Enanta were down around 11% having risen sharply in ...

AstraZeneca is the latest big pharma group to open up a Direct-To-Consumer (DTC) sales channel in the US, offering three of ...

Antibody specialist Genmab has continued its shift from out-licensing drugs to developing its own medicines with a deal to ...

Sarno discusses her favourite memory from Frontiers Health, as well as the importance of equity and accessibility for ...

Walmsley will step down from the board of directors of GSK at the end of the year, and will step down as CEO on 30th ...

Bayer's much-anticipated stem cell therapy for Parkinson's disease is gathering momentum, with dosing in phase 3 trials now underway. The first patient has already been treated with bemdaneprocel, a ...

In this fourth of her series focusing on social media in healthcare, Leanne Orchard explains the opportunities for increasing recruitment to clinical trials through engaging with online patient ...

Oliver Timmis explores the problems associated with securing funding for rare disease research and questions why more funding isn't available in this space. It's difficult to research rare diseases.

Alfasigma's $800 million buyout of Intercept Pharma two years ago is starting to look like a poor bet, as its only approved product, Ocaliva, is pulled off the market in the US and all trials of the ...

uniQure's gene therapy for Huntington's has hit the mark in a clinical trial, raising hopes of the first treatment for the devastating neurodegenerative disease. Shares in the biotech rose sharply ...